文献速递男科与性医学

睾丸癌长期幸存者性功能:全国性队列17年随访

Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup.
PubMed 文献 · J Urol · 2018-05-03

该横断面研究纳入2,260例睾丸癌长期幸存者(中位随访17年),比较不同治疗方式对性功能的影响。以监测为参照,BEP化疗、放疗及多线治疗均增加勃起功能障碍风险,多线治疗风险最高(OR 3.2)。

要点

  • 与监测相比,BEP化疗、放疗及多线治疗均增加勃起功能障碍风险。
  • 多线治疗者勃起功能障碍风险最高(OR 3.2,95%CI 1.6-6.3)。
  • 放疗、BEP化疗后手术及多线治疗与性欲高潮功能障碍相关。

核心结论

  • 与监测相比,BEP化疗、放疗及多线治疗增加睾丸癌长期幸存者勃起功能障碍风险。

研究设计与样本

  • 横断面研究,纳入2,260例睾丸癌长期幸存者,中位随访17年(IQR 12-24)。
  • 治疗分组:监测1,098例,BEP化疗±化疗后腹膜后手术788例,腹部放疗300例,多线治疗74例。
  • 性功能采用IIEF-15问卷评估,以监测为参照进行逻辑回归分析。

主要发现

  • 勃起功能障碍风险:BEP化疗单独OR 1.5(95%CI 1.0-2.1,p<0.05)。
  • 勃起功能障碍风险:BEP化疗联合化疗后手术OR 2.1(95%CI 1.4-3.4,p<0.005)。
  • 勃起功能障碍风险:放疗OR 1.7(95%CI 1.1-2.5,p<0.05)。
  • 勃起功能障碍风险:多线治疗OR 3.2(95%CI 1.6-6.3,p<0.005)。
  • 性欲高潮功能障碍与放疗、BEP化疗联合化疗后手术及多线治疗相关。

临床怎么用

  • 应向睾丸癌患者告知治疗相关远期性功能影响,作为治疗知情信息的一部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evidence on the long-term impact of testicular cancer treatment on sexual function is not clear. Our aim was to estimate the effect of testicular cancer treatment on the risk of sexual dysfunction in long-term survivors of testicular cancer. MATERIALS AND METHODS: We performed a cross-sectional study of 2,260 long-term survivors of testicular cancer with a median followup of 17 years (IQR 12-24), including 1,098 who underwent orchiectomy alone (surveillance), 788 treated with bleomycin, etoposide and cisplatin alone or post-chemotherapy retroperitoneal surgery, 300 treated with abdominal radiotherapy and 74 who received more than 1 line of treatment. Sexual function was evaluated by the IIEF-15 (International Index of Erectile Function-15) questionnaire. Results were compared between treatment groups using logistic regression analysis with the results on each of the 5 IIEF-15 dimensions as the outcome and treatment as exposure using surveillance as the referent. RESULTS: The risk of erectile dysfunction was increased in all treatment groups compared to surveillance, including bleomycin, etoposide and cisplatin alone (OR 1.5, 95% CI 1.0-2.1, p <0.05), bleomycin, etoposide and cisplatin with post-chemotherapy surgery (OR 2.1, 95% CI 1.4-3.4, p <0.005), radiotherapy (OR 1.7, 95% CI 1.1-2.5, p <0.05) and more than 1 line of treatment (OR 3.2, 95% CI 1.6-6.3, p <0.005). Orgasmic dysfunction was associated with radiotherapy, bleomycin, etoposide and cisplatin with post-chemotherapy surgery and more than 1 line of treatment. CONCLUSIONS: Treatment with bleomycin, etoposide and cisplatin, radiotherapy and more than 1 treatment line increased the risk of erectile dysfunction in long-term survivors of testicular cancer compared to surveillance. Patients should be informed about this as part of the information on treatment related late effects.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bandak M, Lauritsen J, Johansen C, et al. Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup. J Urol. 2018. PMID: 29730199. doi:10.1016/j.juro.2018.04.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。